Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1136/bmj.k1315 http://scihub22266oqcxt.onion/10.1136/bmj.k1315 C5915701!5915701!29695481     free     free     free Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       BMJ 2018 ; 361 (ä): ä Nephropedia Template TP {{tp|p=29695481|t=2018. Anticholinergic drugs and risk of dementia: case-control study |pdf=|usr=}}{{29695481}} gab.com Text Anticholinergic drugs and risk of dementia: case-control study JO: BMJ http://www.kidney.de/pget.php?&tw=1&pmid=29695481 #FOAvip Objectives: To estimate the association between the duration and level of exposure to different classes of anticholinergic drugs and subsequent incident dementia. Design: Case-control study. Setting: General practices in the UK contributing to the Clinical Practice Research Datalink. Participants: 40?770 patients aged 65-99 with a diagnosis of dementia between April 2006 and July 2015, and 283?933 controls without dementia. Interventions: Daily defined doses of anticholinergic drugs coded using the Anticholinergic Cognitive Burden (ACB) scale, in total and grouped by subclass, prescribed 4-20 years before a diagnosis of dementia. Main outcome measures: Odds ratios for incident dementia, adjusted for a range of demographic and health related covariates. Results: 14?453 (35%) cases and 86?403 (30%) controls were prescribed at least one anticholinergic drug with an ACB score of 3 (definite anticholinergic activity) during the exposure period. The adjusted odds ratio for any anticholinergic drug with an ACB score of 3 was 1.11 (95% confidence interval 1.08 to 1.14). Dementia was associated with an increasing average ACB score. When considered by drug class, gastrointestinal drugs with an ACB score of 3 were not distinctively linked to dementia. The risk of dementia increased with greater exposure for antidepressant, urological, and antiparkinson drugs with an ACB score of 3. This result was also observed for exposure 15-20 years before a diagnosis. Conclusions: A robust association between some classes of anticholinergic drugs and future dementia incidence was observed. This could be caused by a class specific effect, or by drugs being used for very early symptoms of dementia. Future research should examine anticholinergic drug classes as opposed to anticholinergic effects intrinsically or summing scales for anticholinergic exposure. Trial registration: Registered to the European Union electronic Register of Post-Authorisation Studies EUPAS8705. Twit Text FOAVip Anticholinergic drugs and risk of dementia: case-control study ????BMJ http://www.kidney.de/pget.php?&tw=1&pmid=29695481 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=29695481 #FOAvip English Wikipedia <ref>{{Cite pmid|29695481}}</ref> Anticholinergic drugs and risk of dementia: case-control study #MMPMID29695481 Richardson K; Fox C; Maidment I; Steel N; Loke YK; Arthur A; Myint PK; Grossi CM; Mattishent K; Bennett K; Campbell NL; Boustani M; Robinson L; Brayne C; Matthews FE; Savva GM BMJ 2018[]; 361 (ä): ä PMID29695481show ga Objectives: To estimate the association between the duration and level of exposure to different classes of anticholinergic drugs and subsequent incident dementia. Design: Case-control study. Setting: General practices in the UK contributing to the Clinical Practice Research Datalink. Participants: 40?770 patients aged 65-99 with a diagnosis of dementia between April 2006 and July 2015, and 283?933 controls without dementia. Interventions: Daily defined doses of anticholinergic drugs coded using the Anticholinergic Cognitive Burden (ACB) scale, in total and grouped by subclass, prescribed 4-20 years before a diagnosis of dementia. Main outcome measures: Odds ratios for incident dementia, adjusted for a range of demographic and health related covariates. Results: 14?453 (35%) cases and 86?403 (30%) controls were prescribed at least one anticholinergic drug with an ACB score of 3 (definite anticholinergic activity) during the exposure period. The adjusted odds ratio for any anticholinergic drug with an ACB score of 3 was 1.11 (95% confidence interval 1.08 to 1.14). Dementia was associated with an increasing average ACB score. When considered by drug class, gastrointestinal drugs with an ACB score of 3 were not distinctively linked to dementia. The risk of dementia increased with greater exposure for antidepressant, urological, and antiparkinson drugs with an ACB score of 3. This result was also observed for exposure 15-20 years before a diagnosis. Conclusions: A robust association between some classes of anticholinergic drugs and future dementia incidence was observed. This could be caused by a class specific effect, or by drugs being used for very early symptoms of dementia. Future research should examine anticholinergic drug classes as opposed to anticholinergic effects intrinsically or summing scales for anticholinergic exposure. Trial registration: Registered to the European Union electronic Register of Post-Authorisation Studies EUPAS8705. äAnticholinergic drugs and risk of dementia: case-control study (epmc).pdf DeepDyve Pubget Overpricing